Your browser doesn't support javascript.
loading
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.
Loeb, David M; Lee, Ji Won; Morgenstern, Daniel A; Samson, Yvan; Uyttebroeck, Anne; Lyu, Chuhl Joo; Van Damme, An; Nysom, Karsten; Macy, Margaret E; Zorzi, Alexandra P; Xiong, Julia; Pollert, Petra; Joerg, Ingrid; Vugmeyster, Yulia; Ruisi, Mary; Kang, Hyoung Jin.
Afiliación
  • Loeb DM; Division of Pediatric Hematology, Oncology, and Cellular Therapy, Children's Hospital at Montefiore, Bronx, NY, USA.
  • Lee JW; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Morgenstern DA; Department of Paediatrics, The Hospital for Sick Children, and University of Toronto, Toronto, ON, Canada.
  • Samson Y; Department of Paediatrics, Centre Hospitalier Universitaire Sainte-Justine, University of Montreal, Montreal, QC, Canada.
  • Uyttebroeck A; Department of Pediatric Hematology and Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Lyu CJ; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Van Damme A; Department of Pediatric Hematology and Oncology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Nysom K; Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Macy ME; Department of Pediatrics, University of Colorado Anschutz Medical Campus, and Children's Hospital Colorado, Aurora, CO, USA.
  • Zorzi AP; Children's Hospital, London Health Sciences Centre, London, ON, Canada.
  • Xiong J; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
  • Pollert P; Merck Healthcare KGaA, Darmstadt, Germany.
  • Joerg I; Merck Healthcare KGaA, Darmstadt, Germany.
  • Vugmeyster Y; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
  • Ruisi M; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.
  • Kang HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Wide River Institute of Immunology, Seoul National University Children's Hospital, Seoul, Republic of Korea. kanghj@snu.ac.kr.
Cancer Immunol Immunother ; 71(10): 2485-2495, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35262780
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Neoplasias Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Neoplasias Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos